90% of Healthcare Executives Report Positive ROI From GenAI Investments
Healthcare organizations are increasing their investments in generative artificial intelligence (GenAI), recognizing it as a strategic move that delivers measurable returns. Recent research surveying C-suite executives at healthcare companies with at least $1 billion in annual revenue reveals a strong confidence in GenAI's value. Many have already integrated GenAI into areas like product innovation and customer service, reflecting its growing influence on industries reliant on big data and technology.
The survey highlights that 90% of healthcare executives have seen a positive return on their GenAI investments. This is notable given that technology projects often require significant time and cost before yielding benefits. This success is encouraging more investment, with 59% of healthcare leaders planning to increase their GenAI budgets within the next year—higher than the 52% average across other industries. Full adoption of GenAI in healthcare is expected to take about 7.4 years, matching the general industry pace. Increasing GenAI investment is becoming essential for healthcare companies to stay competitive.
Key Takeaways
High ROI Achievement
Ninety percent of healthcare executives reported positive returns from their GenAI investments. This widespread success confirms the strategic focus on implementing GenAI technologies.
Investment Levels Linked to Returns
Healthcare companies spent an average of $2.7 million on GenAI over the past year. Those seeing very positive returns invested around $6.4 million on average, compared to $2 million for moderate returns and $1.5 million for minimal benefits. This suggests that higher investment levels can lead to better ROI results.
Top Use Cases for GenAI
- About 60% of healthcare CFOs said their companies use GenAI for product and service innovation and for providing real-time automated customer service, such as chatbots.
- Other common applications include data visualization and reporting (55%), information search and access (55%), and workflow automation management (51%).
- However, GenAI deployment remains limited in critical areas like fraud detection and cybersecurity, where firms are proceeding cautiously and focusing investments elsewhere for now.
GenAI is becoming a central part of healthcare operations. Companies must develop clear strategies to maximize its benefits effectively. For professionals interested in expanding their AI skills and knowledge, exploring the latest AI courses can provide practical insights and training.
Your membership also unlocks:
